Advertisement

Topics

Takeda submits NDA for Vedolizumab to treat moderate-to-severe UC in Japan

19:00 EDT 21 Aug 2017 | Pharmaceutical Technology

Takeda Pharmaceutical has filed a new drug application (NDA) for vedolizumab with Japan’s Ministry of Health, Labour and Welfare to treat adult patients with moderately to severely active ulcerative colitis (UC).

Original Article: Takeda submits NDA for Vedolizumab to treat moderate-to-severe UC in Japan

NEXT ARTICLE

More From BioPortfolio on "Takeda submits NDA for Vedolizumab to treat moderate-to-severe UC in Japan"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...